AAV1-NAC32

1 paper5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Health Research Institutes and 1 more

Animals1

Outcomes

Synaptic markers

upin rats1

1 study

AAV1-NAC32 increases synaptic markers in rats.
“NAC32 intrabody expression in the substantia nigra significantly reduced αSyn accumulation, restored TH expression, increased synaptic markers”
AnimalsAAV1-mediated NAC32 intrabody expression
AAV-mediated intracerebral expression of an α-synuclein-targeting intrabody improves motor functions in aged rats
Scientific reports7 Jan 2026

Latest

1 in 12 months

Scientific Reports8 Jan

AAV-mediated intracerebral expression of an α-synuclein-targeting intrabody improves motor functions in aged rats

Experiments in ratsInterventions

Paper

AAV1-NAC32

Outcomes

Latest

AAV-mediated intracerebral expression of an α-synuclein-targeting intrabody improves motor functions in aged rats

Related